Macular degeneration is very common and affects an estimated 19.8 million people in the United States. Approximately one in 10 Americans age 50 and older have an early form of the disease and as many ...

Based on the scientific progress achieved in the past few years, it is possible that patients with myopic macular degeneration complicated by CNV may benefit from a new ophthalmic frontier of ...

From her Oscar-winning turn as Queen Elizabeth I in Shakespeare in Love to her famously gender-swapped role as "M" in the ...

In response to the TGA's approval of a new drug to treat macular degeneration, UNSW researcher Dr Lisa Nivison-Smith provides context about the ...

Breakthroughs in age-related macular degeneration (AMD) treatments have revolutionized the management of this ... Another is to surgically implant them onto the retina using a piece of synthetic or ...

Macular degeneration usually refers to the age-related degenerative changes in the retina that can result in loss of central vision. It is caused by abnormal blood vessel growth (a condition ...

"The laser beam can be positioned with great accuracy on surfaces, so we can produce significantly smaller microlenses than is possible with previously existing methods," commented Thomas Höche head ...

Genome-wide association analyses identify distinct genetic architectures for age-related macular degeneration across ancestries. Nature Genetics , 2024; 56 (12): 2659 DOI: 10.1038/s41588-024-01764 ...

Eleva, a pioneer in unlocking biologics based on a breakthrough manufacturing platform, and 3PBIOVIAN, a contract development ...

Eleva, a German biopharmaceutical company, and 3PBIOVIAN, a global contract development and manufacturing organization (CDMO) ...

Trial registration number NCT01171976. The T&E approach was first introduced by Spaide and Freund in 2007 for neovascular age-related macular degeneration (nAMD), with an aim to reduce patients’ ...